MiNK Therapeutics to show iNKT cell data at SITC 2026
MiNK Therapeutics will present two posters at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting in Phoenix this November, covering distinct but complementary aspects of its allogeneic invariant natural killer T (iNKT) cell platform.
The presentations address a question that sits at the heart of immuno-oncology: how to extend immune-based treatments into tumour types and patient subgroups that have so far failed to respond to checkpoint inhibition.
The data
The first poster examines agenT-797, the company's lead off-the-shelf iNKT candidate, used alone and in combination with Agenus's antibody pair botensilimab and balstilimab in a human organoid model of checkpoint inhibitor-refractory colorectal cancer liver metastases. Microsatellite-stable (MSS) metastatic colorectal cancer is a particularly stubborn target: it accounts for the large majority of metastatic colorectal cases and has shown minimal benefit from the PD-1/PD-L1 class of agents that transformed outcomes in MSS-high tumours. The preclinical work is intended to support the rationale for an ongoing Phase 2 trial at Scripps, led by Darren Sigal, evaluating the same combination in patients with previously treated MSS metastatic colorectal cancer and liver involvement (NCT07550088).
The second poster focuses on senescent cells within the tumour microenvironment, a target that has attracted growing interest as a driver of treatment resistance and stromal remodelling. MiNK will present data from native agenT-797 and its investigational MiNK-215 candidate, an engineered FAP-targeting CAR-iNKT cell incorporating interleukin-15, in oncogenic in vitro models of senescent tumour cells and cancer-associated fibroblasts. The IL-15 component is designed to extend cell persistence, a recognised limitation of first-generation cell therapies in the solid-tumour setting.
Market and competitive context
The iNKT space remains small relative to the broader cell therapy market, which continues to be dominated by autologous and allogeneic CAR-T programmes aimed at haematological malignancies. MiNK's strategy of positioning iNKT cells as off-the-shelf, innate-adaptive bridge therapies differentiates it from the bulk of clinical-stage competitors, though a number of academic and early-commercial groups are pursuing similar biology.
The MSS colorectal cancer opportunity is significant. Multiple approved checkpoint inhibitors have failed to show meaningful activity in MSS tumours, and there is no widely adopted immunotherapy standard of care for the indication. If the combination data with botensilimab and balstilimab hold up in the Phase 2 setting, the readout could attract commercial interest from larger oncology-focused players, though the company has not disclosed any partnership discussions.
The senescent cell angle is earlier-stage and represents a platform bet rather than a near-term clinical programme. Researchers across academia and industry have proposed senolytics and senolytic immune approaches as adjuncts to conventional cancer treatment, but clinical validation remains limited. MiNK's preclinical data at SITC will likely draw attention from translational researchers assessing whether iNKT biology offers a practical route to targeting this compartment.
Both posters will be on display on 6 and 7 November at the Phoenix Convention Center. MiNK is listed on NASDAQ under the ticker INKT.